Selected Antimicrobial Information – Companion Animal
Cefovecin [Companion]
Restriction Status
Unrestricted
Dose
| Species | Usage | Dose |
|---|---|---|
| Cats |
Label dose | 8mg/kg SQ once; therapeutic concentrations are maintained for approximately 7d |
| Treatment of periodontitis/gingivitis or UTI |
Extra-label use | |
| Dogs | Label dose | 8mg/kg SQ once; therapeutic concentrations are maintained for approximately 7-14d (dependent on organism) |
| Treatment of periodontitis/gingivitis or UTI | Extra-label use |
Brand Name(s)
Convenia®
Background
Cefovecin is a bactericidal, time-dependent third generation cephalosporin (β-lactam) antibiotic with a long half-life. Activity against Gram-negative organisms is greater than first or second generation cephalosporins, but less compared to other third-generations cephalosporins. Activity against anaerobes is variable. It is not effective against Enterococcus spp., Pseudomonas aeruginosa, Bordetella bronchiseptica, and methicillin-resistant Staphylococcus spp. Distribution throughout the body is wide and excretion is primarily as active drug in urine.
Acceptable Uses
- Treatment of skin infections (e.g. pyoderma, wounds, abscesses) associated with susceptible Staphylococcus pseudintermedius or Streptococcus canis in dogs, or Pasteurella multocida in cats.
- When used in combination with mechanical cleaning, treatment of periodontitis or gingivitis.
- Less preferred treatment for urinary tract infections when oral treatment is not possible.
Unacceptable Uses
- Generally, less efficacious or ineffective at treating upper respiratory tract disease in cats and dogs.
Formulations Available within the OSU Pharmacy
- Convenia 80mg/ml injectable suspension
Notes
- Long-term excretion in urine (approximately 14d for dogs, 21d for cats) may make interpretation of post-treatment urine cultures difficult.
